These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 27392182)

  • 1. A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.
    Ochs MM; Williams K; Sheung A; Lheritier P; Visan L; Rouleau N; Proust E; de Montfort A; Tang M; Mari K; Hopfer R; Gallichan S; Brookes RH
    Hum Vaccin Immunother; 2016 Nov; 12(11):2946-2952. PubMed ID: 27392182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.
    Brookes RH; Ming M; Williams K; Hopfer R; Gurunathan S; Gallichan S; Tang M; Ochs MM
    Hum Vaccin Immunother; 2015; 11(7):1836-9. PubMed ID: 25912273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
    Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to PcpA and PhtD protect mice against Streptococcus pneumoniae by a macrophage- and complement-dependent mechanism.
    Visan L; Rouleau N; Proust E; Peyrot L; Donadieu A; Ochs M
    Hum Vaccin Immunother; 2018 Feb; 14(2):489-494. PubMed ID: 29135332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
    Xu Q; Pryharski K; Pichichero ME
    Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.
    Ren D; Almudevar AL; Pichichero ME
    Hum Vaccin Immunother; 2015; 11(2):489-97. PubMed ID: 25692218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with a Streptococcus pneumoniae trivalent recombinant PcpA, PhtD and PlyD1 protein vaccine candidate protects against lethal pneumonia in an infant murine model.
    Verhoeven D; Xu Q; Pichichero ME
    Vaccine; 2014 May; 32(26):3205-10. PubMed ID: 24731814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
    Verhoeven D; Perry S; Pichichero ME
    Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
    Seiberling M; Bologa M; Brookes R; Ochs M; Go K; Neveu D; Kamtchoua T; Lashley P; Yuan T; Gurunathan S
    Vaccine; 2012 Dec; 30(52):7455-60. PubMed ID: 23131206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.
    Odutola A; Ota MO; Ogundare EO; Antonio M; Owiafe P; Worwui A; Greenwood B; Alderson M; Traskine M; Verlant V; Dobbelaere K; Borys D
    Hum Vaccin Immunother; 2016; 12(2):393-402. PubMed ID: 26618243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined protective effects of anti-PhtD and anti-pneumococcal polysaccharides.
    Denoël P; Godfroid F; Hermand P; Verlant V; Poolman J
    Vaccine; 2011 Sep; 29(38):6451-3. PubMed ID: 21315695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of higher antibody levels to pneumococcal proteins with protection from pneumococcal acute otitis media but not protection from nasopharyngeal colonization in young children.
    Xu Q; Casey JR; Almudevar A; Pichichero ME
    Clin Microbiol Infect; 2017 Jul; 23(7):487.e1-487.e6. PubMed ID: 28143785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
    Denoël P; Philipp MT; Doyle L; Martin D; Carletti G; Poolman JT
    Vaccine; 2011 Jul; 29(33):5495-501. PubMed ID: 21624422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia.
    Hagerman A; Posfay-Barbe KM; Grillet S; Ochs MM; Brookes RH; Greenberg D; Givon-Lavi N; Dagan R; Siegrist CA
    Clin Microbiol Infect; 2012 Aug; 18(8):756-62. PubMed ID: 21851490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
    Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
    J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
    [No Abstract]   [Full Text] [Related]  

  • 17. Protection against Streptococcus pneumoniae Invasive Pathogenesis by a Protein-Based Vaccine Is Achieved by Suppression of Nasopharyngeal Bacterial Density during Influenza A Virus Coinfection.
    Khan MN; Xu Q; Pichichero ME
    Infect Immun; 2017 Feb; 85(2):. PubMed ID: 27895132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.
    Kaur R; Surendran N; Ochs M; Pichichero ME
    Infect Immun; 2014 Dec; 82(12):5069-75. PubMed ID: 25245804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.
    Xu Q; Surendran N; Verhoeven D; Klapa J; Ochs M; Pichichero ME
    Vaccine; 2015 Feb; 33(8):993-1000. PubMed ID: 25597944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.